When Cannabis Use May Require Extra Caution Before GLP-1 Therapy Cannabis use may require extra caution when symptoms already involve vomiting, poor intake, sedation, abnormal digestion, or blood sugar risk
Source: FDA FDA Warns Patients and Health Care Professionals Not to Use Compounded Drugs from Fullerton Wellness November 1, 2024 -- FDA is warning patients and health care professionals not to use drugs compounded and distributed by Fullerton Wellness LLC, Ontario, Calif., and distributed to patients by medical offices and clinics Fullerton Wellness is a facility that compounds drugs intended to be sterile, including semaglutide and tirzepatide injections
Having a set schedule for this motion gives the plaintiffs time to prepare their potential legal arguments to fight against the companies attempts to sidestep liability
10.1007/s10157-012-0743-y 51 TuomainenT.TaviP
Tirzepatide maintenance: the SURMOUNT-4 evidence The SURMOUNT-4 trial used a randomized-withdrawal design: all participants took open-label tirzepatide for 36 weeks (reaching a mean weight reduction of about 20.9%), then were randomized either to continue the drug or switch to placebo for another 52 weeks